Cargando…
Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins
The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of H...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913237/ https://www.ncbi.nlm.nih.gov/pubmed/33546092 http://dx.doi.org/10.3390/biom11020208 |
_version_ | 1783656759125082112 |
---|---|
author | Kobayakawa, Takuya Yokoyama, Masaru Tsuji, Kohei Fujino, Masayuki Kurakami, Masaki Boku, Sayaka Nakayama, Miyuki Kaneko, Moemi Ohashi, Nami Kotani, Osamu Murakami, Tsutomu Sato, Hironori Tamamura, Hirokazu |
author_facet | Kobayakawa, Takuya Yokoyama, Masaru Tsuji, Kohei Fujino, Masayuki Kurakami, Masaki Boku, Sayaka Nakayama, Miyuki Kaneko, Moemi Ohashi, Nami Kotani, Osamu Murakami, Tsutomu Sato, Hironori Tamamura, Hirokazu |
author_sort | Kobayakawa, Takuya |
collection | PubMed |
description | The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA. |
format | Online Article Text |
id | pubmed-7913237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79132372021-02-28 Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins Kobayakawa, Takuya Yokoyama, Masaru Tsuji, Kohei Fujino, Masayuki Kurakami, Masaki Boku, Sayaka Nakayama, Miyuki Kaneko, Moemi Ohashi, Nami Kotani, Osamu Murakami, Tsutomu Sato, Hironori Tamamura, Hirokazu Biomolecules Communication The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA. MDPI 2021-02-03 /pmc/articles/PMC7913237/ /pubmed/33546092 http://dx.doi.org/10.3390/biom11020208 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Kobayakawa, Takuya Yokoyama, Masaru Tsuji, Kohei Fujino, Masayuki Kurakami, Masaki Boku, Sayaka Nakayama, Miyuki Kaneko, Moemi Ohashi, Nami Kotani, Osamu Murakami, Tsutomu Sato, Hironori Tamamura, Hirokazu Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title | Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title_full | Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title_fullStr | Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title_full_unstemmed | Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title_short | Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins |
title_sort | small-molecule anti-hiv-1 agents based on hiv-1 capsid proteins |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913237/ https://www.ncbi.nlm.nih.gov/pubmed/33546092 http://dx.doi.org/10.3390/biom11020208 |
work_keys_str_mv | AT kobayakawatakuya smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT yokoyamamasaru smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT tsujikohei smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT fujinomasayuki smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT kurakamimasaki smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT bokusayaka smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT nakayamamiyuki smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT kanekomoemi smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT ohashinami smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT kotaniosamu smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT murakamitsutomu smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT satohironori smallmoleculeantihiv1agentsbasedonhiv1capsidproteins AT tamamurahirokazu smallmoleculeantihiv1agentsbasedonhiv1capsidproteins |